Form 4: Jazz Pharma Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Jazz Pharmaceuticals plc Director Rick E. Winningham sold 5,500 ordinary shares at $180.8597 per share in a pre-planned transaction.
Summary
- Rick E. Winningham, a Director of Jazz Pharmaceuticals plc, reported a sale of ordinary shares.
- The transaction involved the disposition of 5,500 ordinary shares.
- The shares were sold at a price of $180.8597 per share.
- Following this transaction, Winningham beneficially owns 8,893 ordinary shares directly.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-planned.
Sentiment
Score: 4
Explanation: A director sold a portion of their holdings, which can be viewed with slight caution by investors, though the transaction was pre-planned under a Rule 10b5-1 plan, indicating it was not based on new, non-public information.
Negatives
- A director sold 5,500 ordinary shares, which could be interpreted with slight caution by the market as a reduction in insider holdings.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Application of Insider Trading Plan | Director Rick E. Winningham executed a sale of shares under a Rule 10b5-1(c) plan. This plan allows insiders to set up a pre-arranged schedule for buying or selling company stock to avoid accusations of trading on material non-public information. | 11/18/2025 | The use of a 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider transactions, providing an affirmative defense against insider trading allegations. |
Stakeholder Impact
- Shareholders: May view the director's sale with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling.
Key Dates
| Date | Description |
|---|---|
| 11/18/2025 | Date of transaction for the sale of ordinary shares. |
| 11/20/2025 | Date the Form 4 was signed and filed. |
Recommendation
holdThe filing reports a routine insider sale by a director under a pre-planned 10b5-1 program. While insider selling can sometimes be a yellow flag, this specific transaction is not indicative of new negative information and appears to be part of a diversification or liquidity strategy. It does not provide sufficient new information to warrant a change in investment recommendation based solely on this filing.
Keywords
Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Share Sale, Director Transaction, Rick E Winningham, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.